Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Acebutolol
- Accession Number
- DB01193 (APRD00772)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
- Structure
Structure for DB01193 (Acebutolol)
- Synonyms
- (±)-acebutolol
- 3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide
- 5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
- Acebutololum
- Acetobutolol
- N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
- N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide
- Product Ingredients
Ingredient UNII CAS InChI Key Acebutolol Hydrochloride B025Y34C54 34381-68-5 KTUFKADDDORSSI-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Acebutolol Tablet 400 mg Oral Sanis Health Inc 2010-02-25 Not applicable Canada 
Acebutolol Tablet 100 mg Oral Sanis Health Inc 2010-02-25 Not applicable Canada Acebutolol Tablet 200 mg Oral Sanis Health Inc 2010-02-25 Not applicable Canada Acebutolol - 400 - Tab 400mg Tablet 400 mg Oral Pro Doc Limitee 1996-12-31 Not applicable Canada Acebutolol-100-tab 100mg Tablet 100 mg Oral Pro Doc Limitee 1996-12-31 Not applicable Canada Acebutolol-200 - Tab 200mg Tablet 200 mg Oral Pro Doc Limitee 1996-12-31 Not applicable Canada Monitan 100 Tablet 100 mg Oral Wyeth Ltd. 1995-12-31 2004-09-13 Canada Monitan 200 Tablet 200 mg Oral Wyeth Ltd. 1995-12-31 2007-01-22 Canada Monitan 400 Tablet 400 mg Oral Wyeth Ltd. 1994-12-31 2007-01-22 Canada Monitan Tab 200mg Tablet 200 mg Oral Wyeth Ltd. 1987-12-31 1996-09-10 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Acebutolol Hydrochloride Capsule 200 mg/1 Oral Av Kare, Inc. 2009-12-14 Not applicable US 
Acebutolol Hydrochloride Capsule 200 mg/1 Oral Marlex Pharmaceuticals Inc 2017-10-20 Not applicable US Acebutolol Hydrochloride Capsule 400 mg/1 Oral Mylan Pharmaceuticals 1995-04-24 Not applicable US Acebutolol Hydrochloride Capsule 200 mg/1 Oral Amneal Pharmaceuticals of New York Llc 2009-12-01 Not applicable US Acebutolol Hydrochloride Capsule 400 mg/1 Oral Av Pak 2009-12-01 2016-10-13 US Acebutolol Hydrochloride Capsule 200 mg/1 Oral Amneal Pharmaceuticals of New York Llc 2009-12-01 Not applicable US Acebutolol Hydrochloride Capsule 200 mg/1 Oral bryant ranch prepack 2009-12-01 2018-01-10 US Acebutolol Hydrochloride Capsule 200 mg/1 Oral Mylan Pharmaceuticals 1995-04-24 Not applicable US Acebutolol Hydrochloride Capsule 200 mg/1 Oral Av Pak 2009-12-01 Not applicable US Acebutolol Hydrochloride Capsule 400 mg/1 Oral Av Kare, Inc. 2009-12-14 Not applicable US - International/Other Brands
- Prent (Bayer)
- Categories
- Adrenergic Agents
- Adrenergic Antagonists
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-Antagonists
- Alcohols
- Amines
- Amino Alcohols
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Beta Blocking Agents
- Beta Blocking Agents and Thiazides
- Beta Blocking Agents, Selective, and Thiazides
- Beta-Blockers (Beta1 Selective)
- Bradycardia-Causing Agents
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inhibitors
- Hypotensive Agents
- Neurotransmitter Agents
- P-glycoprotein/ABCB1 Substrates
- Peripheral Nervous System Agents
- Phenoxypropanolamines
- Propanolamines
- Propanols
- Sympathomimetics
- UNII
- 67P356D8GH
- CAS number
- 37517-30-9
- Weight
- Average: 336.4259
Monoisotopic: 336.204907394 - Chemical Formula
- C18H28N2O4
- InChI Key
- GOEMGAFJFRBGGG-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
- IUPAC Name
- N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide
- SMILES
- CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
Pharmacology
- Indication
For the management of hypertension and ventricular premature beats in adults.
- Structured Indications
- Pharmacodynamics
Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.
- Mechanism of action
Acebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
Target Actions Organism ABeta-1 adrenergic receptor partial agonistHuman UBeta-2 adrenergic receptor partial agonistHuman - Absorption
Well absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In
- Volume of distribution
- Not Available
- Protein binding
26%
- Metabolism
Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).
- Route of elimination
Elimination via renal excretion is approximately 30% to 40% and by non-renal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.
- Half life
The plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Acebutolol Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may decrease the antihypertensive activities of Acebutolol. Investigational 1,10-Phenanthroline 1,10-Phenanthroline may increase the bradycardic activities of Acebutolol. Experimental 4-Methoxyamphetamine 4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Acebutolol. Experimental Aceclofenac Aceclofenac may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Acemetacin The therapeutic efficacy of Acebutolol can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acepromazine Acepromazine may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Aceprometazine Aceprometazine may increase the hypotensive activities of Acebutolol. Approved Acetohexamide Acebutolol may increase the hypoglycemic activities of Acetohexamide. Approved, Investigational, Withdrawn Acetylcholine The risk or severity of adverse effects can be increased when Acebutolol is combined with Acetylcholine. Approved Acetyldigitoxin Acebutolol may increase the bradycardic activities of Acetyldigitoxin. Approved Acetyldigoxin Acebutolol may increase the bradycardic activities of Acetyldigoxin. Experimental Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Adapalene Adapalene may decrease the antihypertensive activities of Acebutolol. Approved Agmatine Agmatine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Experimental, Investigational Alaproclate The serum concentration of Acebutolol can be increased when it is combined with Alaproclate. Experimental Alclofenac Alclofenac may decrease the antihypertensive activities of Acebutolol. Approved, Withdrawn Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol. Approved Alfentanil Alfentanil may increase the bradycardic activities of Acebutolol. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Acebutolol. Approved, Investigational Alimemazine Alimemazine may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Aliskiren Acebutolol may increase the hypotensive activities of Aliskiren. Approved, Investigational Alminoprofen Alminoprofen may decrease the antihypertensive activities of Acebutolol. Experimental Alprenolol Alprenolol may increase the hypotensive activities of Acebutolol. Approved, Withdrawn Ambenonium Ambenonium may increase the bradycardic activities of Acebutolol. Approved Ambrisentan Acebutolol may increase the hypotensive activities of Ambrisentan. Approved, Investigational Ambroxol acefyllinate Acebutolol may decrease the bronchodilatory activities of Ambroxol acefyllinate. Experimental, Investigational Amifostine Acebutolol may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol. Approved Aminophylline Acebutolol may decrease the bronchodilatory activities of Aminophylline. Approved Amiodarone The therapeutic efficacy of Acebutolol can be increased when used in combination with Amiodarone. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Acebutolol. Approved Amobarbital The serum concentration of Acebutolol can be decreased when it is combined with Amobarbital. Approved, Illicit Amodiaquine The metabolism of Acebutolol can be decreased when combined with Amodiaquine. Approved, Investigational Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Acebutolol is combined with Amyl Nitrite. Approved Andrographolide Andrographolide may decrease the antihypertensive activities of Acebutolol. Investigational Anisodamine Anisodamine may decrease the antihypertensive activities of Acebutolol. Investigational Antipyrine Antipyrine may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Apalutamide The serum concentration of Acebutolol can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin Apocynin may decrease the antihypertensive activities of Acebutolol. Investigational Apomorphine Apomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Apraclonidine is combined with Acebutolol. Approved Apremilast Apremilast may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Arbutamine Acebutolol may decrease the bronchodilatory activities of Arbutamine. Approved Arecoline The risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline. Experimental Arformoterol Acebutolol may decrease the bronchodilatory activities of Arformoterol. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Acebutolol. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Acebutolol. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Acebutolol. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Acebutolol. Approved Atomoxetine Atomoxetine may increase the hypertensive activities of Acebutolol. Approved Avanafil Avanafil may increase the antihypertensive activities of Acebutolol. Approved Azapropazone Azapropazone may decrease the antihypertensive activities of Acebutolol. Withdrawn Azelastine Azelastine may decrease the antihypertensive activities of Acebutolol. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil. Approved, Investigational Balsalazide Balsalazide may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Bambuterol Acebutolol may decrease the bronchodilatory activities of Bambuterol. Approved, Investigational Barbexaclone The serum concentration of Acebutolol can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Acebutolol can be decreased when it is combined with Barbital. Illicit Barnidipine Acebutolol may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Acebutolol. Approved, Investigational Bendazac Bendazac may decrease the antihypertensive activities of Acebutolol. Experimental Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Acebutolol. Approved Benmoxin Benmoxin may increase the hypotensive activities of Acebutolol. Withdrawn Benorilate Benorilate may decrease the antihypertensive activities of Acebutolol. Experimental Benoxaprofen Benoxaprofen may decrease the antihypertensive activities of Acebutolol. Withdrawn Benzphetamine Benzphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Illicit Benzydamine Benzydamine may decrease the antihypertensive activities of Acebutolol. Approved Bepridil Acebutolol may increase the hypotensive activities of Bepridil. Approved, Withdrawn Beractant Acebutolol may increase the bradycardic activities of Beractant. Approved Betaxolol Betaxolol may increase the hypotensive activities of Acebutolol. Approved, Investigational Bethanechol The risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol. Approved Bethanidine Bethanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Bevonium Bevonium may decrease the antihypertensive activities of Acebutolol. Experimental Bietaserpine Bietaserpine may increase the hypotensive activities of Acebutolol. Experimental Bimatoprost Bimatoprost may increase the hypotensive activities of Acebutolol. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Acebutolol. Approved BL-1020 BL-1020 may increase the hypotensive activities of Acebutolol. Investigational Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Acebutolol. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Acebutolol. Approved, Investigational BQ-123 Acebutolol may increase the hypotensive activities of BQ-123. Investigational Bretylium Bretylium may increase the bradycardic activities of Acebutolol. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Acebutolol. Approved Brofaromine Brofaromine may increase the hypotensive activities of Acebutolol. Experimental Bromfenac Bromfenac may decrease the antihypertensive activities of Acebutolol. Approved Bromocriptine Bromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Bucillamine Bucillamine may decrease the antihypertensive activities of Acebutolol. Investigational Bucindolol Acebutolol may increase the orthostatic hypotensive activities of Bucindolol. Investigational Bufexamac Bufexamac may decrease the antihypertensive activities of Acebutolol. Approved, Experimental Bumadizone Bumadizone may decrease the antihypertensive activities of Acebutolol. Experimental Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol. Approved Bunazosin Acebutolol may increase the orthostatic hypotensive activities of Bunazosin. Investigational Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Acebutolol. Approved, Investigational Bupranolol Acebutolol may increase the hypotensive activities of Bupranolol. Approved Cabergoline Acebutolol may increase the vasoconstricting activities of Cabergoline. Approved Cadralazine Cadralazine may increase the hypotensive activities of Acebutolol. Experimental Cafedrine Acebutolol may increase the hypotensive activities of Cafedrine. Investigational Calfactant Acebutolol may increase the bradycardic activities of Calfactant. Approved Canagliflozin The risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin. Approved Candesartan Acebutolol may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Candesartan cilexetil may increase the hypotensive activities of Acebutolol. Approved Candoxatril Candoxatril may increase the hypotensive activities of Acebutolol. Experimental Captopril Acebutolol may increase the hypotensive activities of Captopril. Approved Carbachol The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbachol. Approved Carbaspirin calcium Carbaspirin calcium may decrease the antihypertensive activities of Acebutolol. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Acebutolol. Approved, Investigational Carbutamide Acebutolol may increase the hypoglycemic activities of Carbutamide. Experimental Caroxazone Caroxazone may increase the hypotensive activities of Acebutolol. Withdrawn Carprofen Carprofen may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the hypotensive activities of Acebutolol. Approved Carvedilol Acebutolol may increase the orthostatic hypotensive activities of Carvedilol. Approved, Investigational Castanospermine Castanospermine may decrease the antihypertensive activities of Acebutolol. Experimental Celecoxib Celecoxib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Celiprolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Celiprolol. Approved, Investigational Ceritinib Acebutolol may increase the bradycardic activities of Ceritinib. Approved Cevimeline The risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline. Approved Chloroquine The metabolism of Acebutolol can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Chlorphentermine The risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine. Illicit, Withdrawn Chlorproethazine Chlorproethazine may increase the hypotensive activities of Acebutolol. Experimental Chlorpromazine Chlorpromazine may increase the hypotensive activities of Acebutolol. Approved, Investigational, Vet Approved Chlorpropamide Acebutolol may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorthalidone Chlorthalidone may increase the hypotensive activities of Acebutolol. Approved Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the antihypertensive activities of Acebutolol. Approved Cicletanine Acebutolol may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Acebutolol may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Acebutolol. Approved, Investigational Clenbuterol The risk or severity of adverse effects can be increased when Acebutolol is combined with Clenbuterol. Approved, Investigational, Vet Approved Clevidipine The risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Acebutolol. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Acebutolol. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Clonixin Clonixin may decrease the antihypertensive activities of Acebutolol. Approved Cloranolol Acebutolol may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Acebutolol. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Acebutolol. Approved, Investigational Coumaphos Coumaphos may increase the bradycardic activities of Acebutolol. Vet Approved Crizotinib Acebutolol may increase the bradycardic activities of Crizotinib. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Acebutolol. Approved Curcumin Curcumin may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Cyclopenthiazide Acebutolol may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclothiazide Cyclothiazide may increase the hypotensive activities of Acebutolol. Approved Cymarin Acebutolol may increase the bradycardic activities of Cymarin. Experimental Dapagliflozin The risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin. Approved Dapoxetine The serum concentration of Acebutolol can be increased when it is combined with Dapoxetine. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Acebutolol. Approved, Investigational Decamethonium Decamethonium may increase the bradycardic activities of Acebutolol. Approved Delapril Acebutolol may increase the hypotensive activities of Delapril. Experimental Demecarium Demecarium may increase the bradycardic activities of Acebutolol. Approved Deserpidine Acebutolol may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Acebutolol. Approved Deslanoside Acebutolol may increase the bradycardic activities of Deslanoside. Approved Desvenlafaxine The serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine. Approved, Investigational Dexmedetomidine Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Acebutolol. Approved Dichlorvos Dichlorvos may increase the bradycardic activities of Acebutolol. Vet Approved Diclofenac Diclofenac may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol. Approved, Investigational Diethylnorspermine Acebutolol may increase the hypotensive activities of Diethylnorspermine. Investigational Difenpiramide Difenpiramide may decrease the antihypertensive activities of Acebutolol. Experimental Diflunisal Diflunisal may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Digitoxin Acebutolol may increase the bradycardic activities of Digitoxin. Approved, Investigational Digoxin Acebutolol may increase the bradycardic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Acebutolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine). Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Dihydroergotamine Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Diltiazem Diltiazem may increase the hypotensive activities of Acebutolol. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab. Approved, Investigational Dipivefrin Dipivefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Dipyridamole Dipyridamole may increase the bradycardic activities of Acebutolol. Approved Disopyramide Disopyramide may increase the bradycardic activities of Acebutolol. Approved Distigmine Distigmine may increase the bradycardic activities of Acebutolol. Experimental Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Acebutolol. Approved Donepezil Donepezil may increase the bradycardic activities of Acebutolol. Approved Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Acebutolol. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Acebutolol. Approved Doxazosin Acebutolol may increase the orthostatic hypotensive activities of Doxazosin. Approved Doxofylline The risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline. Approved, Investigational Dronabinol Dronabinol may increase the tachycardic activities of Acebutolol. Approved, Illicit Dronedarone Dronedarone may increase the bradycardic activities of Acebutolol. Approved Droxicam Droxicam may decrease the antihypertensive activities of Acebutolol. Withdrawn Droxidopa Droxidopa may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Duloxetine Acebutolol may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib Duvelisib may decrease the antihypertensive activities of Acebutolol. Investigational Dyphylline Acebutolol may decrease the bronchodilatory activities of Dyphylline. Approved E-6201 E-6201 may decrease the antihypertensive activities of Acebutolol. Investigational Echothiophate Echothiophate may increase the bradycardic activities of Acebutolol. Approved Edrophonium Edrophonium may increase the bradycardic activities of Acebutolol. Approved Efonidipine Acebutolol may increase the hypotensive activities of Efonidipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Enalaprilat Acebutolol may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Acebutolol. Experimental Epanolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Epanolol. Experimental Ephedra Ephedra may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Nutraceutical, Withdrawn Ephedrine The risk or severity of adverse effects can be increased when Acebutolol is combined with Ephedrine. Approved Epibatidine The risk or severity of adverse effects can be increased when Acebutolol is combined with Epibatidine. Experimental Epinephrine Epinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Vet Approved Epirizole Epirizole may decrease the antihypertensive activities of Acebutolol. Approved Eplerenone The risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol. Approved Epoprostenol Acebutolol may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Eprosartan may increase the hypotensive activities of Acebutolol. Approved Ergoloid mesylate Acebutolol may increase the vasoconstricting activities of Ergoloid mesylate. Approved Ergonovine Acebutolol may increase the vasoconstricting activities of Ergonovine. Approved Ergotamine Ergotamine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol. Approved, Investigational Etanercept Etanercept may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Ethenzamide Ethenzamide may decrease the antihypertensive activities of Acebutolol. Experimental Etilefrine The risk or severity of adverse effects can be increased when Acebutolol is combined with Etilefrine. Withdrawn Etodolac Etodolac may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Vet Approved Etofenamate Etofenamate may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Etomidate Etomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Etoperidone The serum concentration of Acebutolol can be increased when it is combined with Etoperidone. Withdrawn Etoricoxib Etoricoxib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Evening primrose oil Evening primrose oil may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Exisulind Exisulind may decrease the antihypertensive activities of Acebutolol. Investigational Felbinac Felbinac may decrease the antihypertensive activities of Acebutolol. Experimental Felodipine Felodipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Fenbufen Fenbufen may decrease the antihypertensive activities of Acebutolol. Approved Fenoldopam Fenoldopam may increase the hypotensive activities of Acebutolol. Approved Fenoprofen Fenoprofen may decrease the antihypertensive activities of Acebutolol. Approved Fenoterol The risk or severity of adverse effects can be increased when Acebutolol is combined with Fenoterol. Approved, Investigational Fenozolone The risk or severity of adverse effects can be increased when Acebutolol is combined with Fenozolone. Experimental Fentanyl Fentanyl may increase the bradycardic activities of Acebutolol. Approved, Illicit, Investigational, Vet Approved Fenthion Fenthion may increase the bradycardic activities of Acebutolol. Vet Approved Fentiazac Fentiazac may decrease the antihypertensive activities of Acebutolol. Experimental Feprazone Feprazone may decrease the antihypertensive activities of Acebutolol. Experimental Ferulic acid Acebutolol may increase the hypotensive activities of Ferulic acid. Experimental Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Acebutolol. Approved, Investigational Fingolimod Acebutolol may increase the bradycardic activities of Fingolimod. Approved, Investigational Floctafenine The risk or severity of adverse effects can be increased when Acebutolol is combined with Floctafenine. Approved, Withdrawn Flunixin Flunixin may decrease the antihypertensive activities of Acebutolol. Vet Approved Flunoxaprofen Flunoxaprofen may decrease the antihypertensive activities of Acebutolol. Experimental Fluoxetine The serum concentration of Acebutolol can be increased when it is combined with Fluoxetine. Approved, Vet Approved Fluphenazine Fluphenazine may increase the hypotensive activities of Acebutolol. Approved Flurbiprofen Flurbiprofen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Formoterol Acebutolol may decrease the bronchodilatory activities of Formoterol. Approved, Investigational Fosinopril Fosinopril may increase the hypotensive activities of Acebutolol. Approved Furazolidone Furazolidone may increase the hypotensive activities of Acebutolol. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol. Approved, Vet Approved Galantamine Galantamine may increase the bradycardic activities of Acebutolol. Approved Gallamine Triethiodide Gallamine Triethiodide may increase the bradycardic activities of Acebutolol. Approved Gitoformate Acebutolol may increase the bradycardic activities of Gitoformate. Experimental Glibornuride Acebutolol may increase the hypoglycemic activities of Glibornuride. Investigational, Withdrawn Gliclazide Acebutolol may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Acebutolol may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Acebutolol may increase the hypoglycemic activities of Glipizide. Approved, Investigational Gliquidone Acebutolol may increase the hypoglycemic activities of Gliquidone. Approved, Investigational Glisoxepide Acebutolol may increase the hypoglycemic activities of Glisoxepide. Investigational Glyburide Acebutolol may increase the hypoglycemic activities of Glyburide. Approved GTS-21 The risk or severity of adverse effects can be increased when Acebutolol is combined with GTS-21. Investigational Guacetisal Guacetisal may decrease the antihypertensive activities of Acebutolol. Experimental Guanabenz Guanabenz may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Acebutolol. Approved Guanazodine Acebutolol may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Acebutolol. Approved Guanfacine Guanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Guanoclor Acebutolol may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Acebutolol may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Acebutolol may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Acebutolol. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Acebutolol. Experimental Hexamethonium Acebutolol may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital The serum concentration of Acebutolol can be decreased when it is combined with Hexobarbital. Approved Higenamine Higenamine may decrease the antihypertensive activities of Acebutolol. Investigational Huperzine A Huperzine A may increase the bradycardic activities of Acebutolol. Approved, Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Acebutolol. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Acebutolol. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Acebutolol. Approved, Investigational Hydroxyamphetamine The risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine. Approved Hydroxychloroquine The metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine. Approved Ibuprofen Ibuprofen may decrease the antihypertensive activities of Acebutolol. Approved Ibuproxam Ibuproxam may decrease the antihypertensive activities of Acebutolol. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Acebutolol. Approved, Investigational Imidapril Acebutolol may increase the hypotensive activities of Imidapril. Investigational Imidazole salicylate Imidazole salicylate may decrease the antihypertensive activities of Acebutolol. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Acebutolol. Approved Indacaterol Acebutolol may decrease the bronchodilatory activities of Indacaterol. Approved Indalpine The serum concentration of Acebutolol can be increased when it is combined with Indalpine. Investigational, Withdrawn Indapamide Indapamide may increase the hypotensive activities of Acebutolol. Approved Indenolol Acebutolol may increase the hypotensive activities of Indenolol. Withdrawn Indobufen Indobufen may decrease the antihypertensive activities of Acebutolol. Investigational Indomethacin Indomethacin may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Indoprofen Indoprofen may decrease the antihypertensive activities of Acebutolol. Withdrawn Indoramin Acebutolol may increase the orthostatic hypotensive activities of Indoramin. Withdrawn Insulin Human Acebutolol may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Pork Acebutolol may increase the hypoglycemic activities of Insulin Pork. Approved Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Acebutolol. Approved, Investigational Ipidacrine Ipidacrine may increase the bradycardic activities of Acebutolol. Experimental Iproclozide Iproclozide may increase the hypotensive activities of Acebutolol. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Acebutolol. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Acebutolol. Approved, Investigational Isavuconazole The serum concentration of Acebutolol can be increased when it is combined with Isavuconazole. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Acebutolol. Approved Isoetarine Acebutolol may decrease the bronchodilatory activities of Isoetarine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Acebutolol. Approved, Vet Approved Isoflurophate Isoflurophate may increase the bradycardic activities of Acebutolol. Approved, Investigational, Withdrawn Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Acebutolol. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol. Approved Isoxicam Isoxicam may decrease the antihypertensive activities of Acebutolol. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Acebutolol is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Ivabradine Acebutolol may increase the bradycardic activities of Ivabradine. Approved Kebuzone Kebuzone may decrease the antihypertensive activities of Acebutolol. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Acebutolol. Investigational Ketoprofen Ketoprofen may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Ketorolac Ketorolac may decrease the antihypertensive activities of Acebutolol. Approved Labetalol Acebutolol may increase the orthostatic hypotensive activities of Labetalol. Approved Lacidipine Acebutolol may increase the hypotensive activities of Lacidipine. Approved, Investigational Lacosamide Acebutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide. Approved Lanatoside C Acebutolol may increase the bradycardic activities of Lanatoside C. Experimental Lanreotide Acebutolol may increase the bradycardic activities of Lanreotide. Approved Latanoprost Latanoprost may increase the hypotensive activities of Acebutolol. Approved, Investigational Leflunomide Leflunomide may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Acebutolol. Approved, Investigational Levodopa Acebutolol may increase the orthostatic hypotensive activities of Levodopa. Approved Levomilnacipran The serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran. Approved, Investigational Levonordefrin Levonordefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Levosalbutamol Acebutolol may decrease the bronchodilatory activities of Levosalbutamol. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Acebutolol. Approved, Investigational Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Acebutolol. Approved, Vet Approved Linezolid Linezolid may increase the hypertensive activities of Acebutolol. Approved, Investigational Linsidomine Acebutolol may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Acebutolol. Approved, Investigational Lisofylline Lisofylline may decrease the antihypertensive activities of Acebutolol. Investigational Lobeline The risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline. Investigational Lofexidine Lofexidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Lonazolac Lonazolac may decrease the antihypertensive activities of Acebutolol. Experimental Lornoxicam Lornoxicam may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Losartan Losartan may increase the hypotensive activities of Acebutolol. Approved Loxoprofen Loxoprofen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Lucinactant Acebutolol may increase the bradycardic activities of Lucinactant. Approved, Investigational Lumacaftor The serum concentration of Acebutolol can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib Lumiracoxib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Macitentan Acebutolol may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate Magnesium salicylate may decrease the antihypertensive activities of Acebutolol. Approved Malathion Malathion may increase the bradycardic activities of Acebutolol. Approved, Investigational Manidipine Acebutolol may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol. Approved, Investigational Masoprocol Masoprocol may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Acebutolol. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Acebutolol. Approved, Investigational Meclofenamic acid Meclofenamic acid may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Mefenamic acid Mefenamic acid may decrease the antihypertensive activities of Acebutolol. Approved Mefenorex The risk or severity of adverse effects can be increased when Acebutolol is combined with Mefenorex. Experimental Mefloquine Mefloquine may increase the bradycardic activities of Acebutolol. Approved, Investigational Meloxicam Meloxicam may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Memantine Memantine may increase the bradycardic activities of Acebutolol. Approved, Investigational Mephentermine The risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine. Approved Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Acebutolol. Approved, Vet Approved Mesalazine Mesalazine may decrease the antihypertensive activities of Acebutolol. Approved Mesoridazine Mesoridazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Metahexamide Acebutolol may increase the hypoglycemic activities of Metahexamide. Experimental Metamizole Metamizole may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Withdrawn Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol. Approved, Investigational Methacholine Acebutolol may increase the bronchoconstrictory activities of Methacholine. Approved, Investigational Methamphetamine Methamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Illicit Methanesulfonyl Fluoride Methanesulfonyl Fluoride may increase the bradycardic activities of Acebutolol. Investigational Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Acebutolol. Approved Methohexital The serum concentration of Acebutolol can be decreased when it is combined with Methohexital. Approved Methoserpidine Acebutolol may increase the hypotensive activities of Methoserpidine. Experimental Methotrimeprazine Methotrimeprazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Acebutolol. Approved, Investigational Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol. Approved Methyldopa Methyldopa may increase the hypotensive activities of Acebutolol. Approved Methylene blue Methylene blue may increase the hypotensive activities of Acebutolol. Approved, Investigational Methylergometrine Acebutolol may increase the vasoconstricting activities of Methylergometrine. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Methylphenobarbital The serum concentration of Acebutolol can be decreased when it is combined with Methylphenobarbital. Approved Metildigoxin Acebutolol may increase the bradycardic activities of Metildigoxin. Experimental Metipranolol Acebutolol may increase the hypotensive activities of Metipranolol. Approved Metoclopramide Metoclopramide may increase the bradycardic activities of Acebutolol. Approved, Investigational Metolazone Metolazone may increase the hypotensive activities of Acebutolol. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Acebutolol. Approved, Investigational Metyrosine Acebutolol may increase the hypotensive activities of Metyrosine. Approved Mibefradil Acebutolol may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midodrine Acebutolol may increase the bradycardic activities of Midodrine. Approved Milnacipran The serum concentration of Acebutolol can be increased when it is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the bradycardic activities of Acebutolol. Approved Minoxidil Minoxidil may increase the hypotensive activities of Acebutolol. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Acebutolol. Investigational Mizoribine Mizoribine may decrease the antihypertensive activities of Acebutolol. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Acebutolol. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Acebutolol. Approved Mofebutazone Mofebutazone may decrease the antihypertensive activities of Acebutolol. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Acebutolol. Approved, Investigational Moricizine Moricizine may increase the hypotensive activities of Acebutolol. Approved, Investigational, Withdrawn Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Acebutolol. Approved, Investigational Moxonidine Moxonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Muzolimine Acebutolol may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil Mycophenolate mofetil may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Mycophenolic acid Mycophenolic acid may decrease the antihypertensive activities of Acebutolol. Approved Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Acebutolol. Approved, Investigational Nabumetone Nabumetone may decrease the antihypertensive activities of Acebutolol. Approved Nadolol Acebutolol may increase the hypotensive activities of Nadolol. Approved Nafamostat Nafamostat may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Naftifine Naftifine may decrease the antihypertensive activities of Acebutolol. Approved Naftopidil Acebutolol may increase the hypotensive activities of Naftopidil. Investigational Naphazoline Naphazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Naproxen Naproxen may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Nebivolol Acebutolol may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The serum concentration of Acebutolol can be increased when it is combined with Nefazodone. Approved, Withdrawn Neostigmine Neostigmine may increase the bradycardic activities of Acebutolol. Approved, Vet Approved Nepafenac Nepafenac may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Acebutolol is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Acebutolol. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Acebutolol. Approved, Investigational Nicotine The risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine. Approved Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Acebutolol. Approved Nifenazone Nifenazone may decrease the antihypertensive activities of Acebutolol. Experimental Niflumic Acid Niflumic Acid may decrease the antihypertensive activities of Acebutolol. Approved Niguldipine Acebutolol may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Acebutolol may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide Nimesulide may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Acebutolol. Approved Nitrendipine Nitrendipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acebutolol. Approved Nitroaspirin Nitroaspirin may decrease the antihypertensive activities of Acebutolol. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Acebutolol. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Acebutolol. Approved, Investigational Norepinephrine Norepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Nylidrin The risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin. Approved Obinutuzumab Acebutolol may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Acebutolol. Withdrawn Octreotide Octreotide may increase the bradycardic activities of Acebutolol. Approved, Investigational Oleandrin Acebutolol may increase the bradycardic activities of Oleandrin. Experimental, Investigational Olmesartan Olmesartan may increase the hypotensive activities of Acebutolol. Approved, Investigational Olodaterol Acebutolol may decrease the bronchodilatory activities of Olodaterol. Approved Olopatadine Olopatadine may decrease the antihypertensive activities of Acebutolol. Approved Olsalazine Olsalazine may decrease the antihypertensive activities of Acebutolol. Approved Omapatrilat Omapatrilat may increase the hypotensive activities of Acebutolol. Investigational Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Acebutolol. Approved Orgotein Orgotein may decrease the antihypertensive activities of Acebutolol. Vet Approved Ouabain Acebutolol may increase the bradycardic activities of Ouabain. Approved Oxaprozin Oxaprozin may decrease the antihypertensive activities of Acebutolol. Approved Oxprenolol Acebutolol may increase the hypotensive activities of Oxprenolol. Approved Oxymetazoline Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Oxyphenbutazone Oxyphenbutazone may decrease the antihypertensive activities of Acebutolol. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Acebutolol. Approved, Vet Approved Paliperidone Paliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Papaverine The risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol. Approved, Investigational Paraoxon Paraoxon may increase the bradycardic activities of Acebutolol. Experimental Parecoxib Parecoxib may decrease the antihypertensive activities of Acebutolol. Approved Pargyline Pargyline may increase the hypotensive activities of Acebutolol. Approved Paroxetine The serum concentration of Acebutolol can be increased when it is combined with Paroxetine. Approved, Investigational Parthenolide Parthenolide may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Pasireotide Acebutolol may increase the bradycardic activities of Pasireotide. Approved Penbutolol Acebutolol may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentobarbital The serum concentration of Acebutolol can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Pentolinium Pentolinium may increase the hypotensive activities of Acebutolol. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Acebutolol. Approved, Investigational Perazine Perazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Pergolide Pergolide may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational, Vet Approved, Withdrawn Perindopril Perindopril may increase the hypotensive activities of Acebutolol. Approved Perphenazine Perphenazine may increase the hypotensive activities of Acebutolol. Approved Peruvoside Acebutolol may increase the bradycardic activities of Peruvoside. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Acebutolol. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Acebutolol. Withdrawn Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol. Approved, Illicit Phenobarbital The serum concentration of Acebutolol can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Acebutolol. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Acebutolol. Withdrawn Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol. Approved, Illicit Phentolamine Phentolamine may increase the hypotensive activities of Acebutolol. Approved Phenylbutazone Phenylbutazone may decrease the antihypertensive activities of Acebutolol. Approved, Vet Approved Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Acebutolol. Approved, Vet Approved, Withdrawn Physostigmine Physostigmine may increase the bradycardic activities of Acebutolol. Approved, Investigational Pilocarpine The risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine. Approved, Investigational Pimecrolimus Pimecrolimus may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Acebutolol. Approved Pindolol Pindolol may increase the hypotensive activities of Acebutolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Acebutolol. Approved, Investigational Pirbuterol Acebutolol may decrease the bronchodilatory activities of Pirbuterol. Approved Pirfenidone Pirfenidone may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Acebutolol. Approved Piroxicam Piroxicam may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Pirprofen Pirprofen may decrease the antihypertensive activities of Acebutolol. Experimental Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Acebutolol. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypotensive activities of Acebutolol. Withdrawn Platelet Activating Factor Acebutolol may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Acebutolol may increase the hypotensive activities of Polythiazide. Approved Poractant alfa Acebutolol may increase the bradycardic activities of Poractant alfa. Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Acebutolol. Approved, Investigational Pranoprofen Pranoprofen may decrease the antihypertensive activities of Acebutolol. Experimental, Investigational Prazosin Acebutolol may increase the orthostatic hypotensive activities of Prazosin. Approved Prenalterol The risk or severity of adverse effects can be increased when Acebutolol is combined with Prenalterol. Experimental Primaquine The metabolism of Acebutolol can be decreased when combined with Primaquine. Approved Primidone The serum concentration of Acebutolol can be decreased when it is combined with Primidone. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Procaterol The risk or severity of adverse effects can be increased when Acebutolol is combined with Procaterol. Approved, Investigational Prochlorperazine Prochlorperazine may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Proglumetacin Proglumetacin may decrease the antihypertensive activities of Acebutolol. Experimental Promazine Promazine may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Promethazine Promethazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Propacetamol Propacetamol may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Propafenone The serum concentration of Acebutolol can be increased when it is combined with Propafenone. Approved Propericiazine Propericiazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Propiopromazine Propiopromazine may increase the hypotensive activities of Acebutolol. Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Acebutolol. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Acebutolol. Approved, Investigational Propyphenazone Propyphenazone may decrease the antihypertensive activities of Acebutolol. Experimental Proquazone Proquazone may decrease the antihypertensive activities of Acebutolol. Experimental Proscillaridin Acebutolol may increase the bradycardic activities of Proscillaridin. Experimental Protokylol Acebutolol may decrease the bronchodilatory activities of Protokylol. Approved, Vet Approved Pseudoephedrine Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved PTC299 PTC299 may decrease the antihypertensive activities of Acebutolol. Investigational Pyridostigmine Pyridostigmine may increase the bradycardic activities of Acebutolol. Approved, Investigational Quetiapine The risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine. Approved Quinapril Quinapril may increase the hypotensive activities of Acebutolol. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Acebutolol. Approved Racepinephrine Racepinephrine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved Ramipril Ramipril may increase the hypotensive activities of Acebutolol. Approved Ranolazine The serum concentration of Acebutolol can be increased when it is combined with Ranolazine. Approved, Investigational Rasagiline Rasagiline may increase the hypotensive activities of Acebutolol. Approved Regorafenib Regorafenib may increase the bradycardic activities of Acebutolol. Approved Remifentanil Remifentanil may increase the bradycardic activities of Acebutolol. Approved Remikiren Remikiren may increase the hypotensive activities of Acebutolol. Approved Rescinnamine Acebutolol may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Acebutolol. Approved, Investigational Resveratrol Resveratrol may decrease the antihypertensive activities of Acebutolol. Approved, Experimental, Investigational Rifampicin The serum concentration of Acebutolol can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Acebutolol can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Acebutolol can be decreased when it is combined with Rifaximin. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Acebutolol. Approved, Investigational Riociguat Acebutolol may increase the hypotensive activities of Riociguat. Approved Risperidone Acebutolol may increase the hypotensive activities of Risperidone. Approved, Investigational Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Acebutolol. Approved, Investigational Rituximab Acebutolol may increase the hypotensive activities of Rituximab. Approved Rivastigmine Acebutolol may increase the bradycardic activities of Rivastigmine. Approved, Investigational Rofecoxib Rofecoxib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Withdrawn Ropinirole Ropinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acebutolol. Approved Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Acebutolol. Approved Ruxolitinib Ruxolitinib may increase the bradycardic activities of Acebutolol. Approved Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Acebutolol. Approved Safrazine Safrazine may increase the hypotensive activities of Acebutolol. Withdrawn Salbutamol Acebutolol may decrease the bronchodilatory activities of Salbutamol. Approved, Vet Approved Salicylamide Salicylamide may decrease the antihypertensive activities of Acebutolol. Approved Salicylic acid Salicylic acid may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Vet Approved Salmeterol Acebutolol may decrease the bronchodilatory activities of Salmeterol. Approved Salsalate Salsalate may decrease the antihypertensive activities of Acebutolol. Approved Saprisartan Acebutolol may increase the hypotensive activities of Saprisartan. Experimental Secobarbital The serum concentration of Acebutolol can be decreased when it is combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Acebutolol. Approved, Investigational, Vet Approved Selexipag Acebutolol may increase the hypotensive activities of Selexipag. Approved Semapimod Semapimod may decrease the antihypertensive activities of Acebutolol. Investigational Seratrodast Seratrodast may decrease the antihypertensive activities of Acebutolol. Approved Serrapeptase Serrapeptase may decrease the antihypertensive activities of Acebutolol. Investigational Sertraline The serum concentration of Acebutolol can be increased when it is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Acebutolol. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Acebutolol. Approved, Investigational Silodosin Acebutolol may increase the orthostatic hypotensive activities of Silodosin. Approved Sitaxentan Acebutolol may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol. Approved Spirapril Acebutolol may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol. Approved SRT501 SRT501 may decrease the antihypertensive activities of Acebutolol. Investigational Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol. Approved, Investigational Sufentanil Sufentanil may increase the bradycardic activities of Acebutolol. Approved, Investigational Sulfasalazine Sulfasalazine may decrease the antihypertensive activities of Acebutolol. Approved Sulindac Sulindac may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Suprofen Suprofen may decrease the antihypertensive activities of Acebutolol. Approved, Withdrawn Suxibuzone Suxibuzone may decrease the antihypertensive activities of Acebutolol. Experimental Synephrine The risk or severity of adverse effects can be increased when Acebutolol is combined with Synephrine. Experimental Tacrine Tacrine may increase the bradycardic activities of Acebutolol. Investigational, Withdrawn Tadalafil Tadalafil may increase the antihypertensive activities of Acebutolol. Approved, Investigational Talinolol Acebutolol may increase the hypotensive activities of Talinolol. Investigational Tamsulosin Acebutolol may increase the orthostatic hypotensive activities of Tamsulosin. Approved, Investigational Tarenflurbil Tarenflurbil may decrease the antihypertensive activities of Acebutolol. Investigational Tedizolid Phosphate Tedizolid Phosphate may increase the hypertensive activities of Acebutolol. Approved Telmisartan Telmisartan may increase the hypotensive activities of Acebutolol. Approved, Investigational Temocapril Acebutolol may increase the hypotensive activities of Temocapril. Experimental, Investigational Tenidap Tenidap may decrease the antihypertensive activities of Acebutolol. Experimental Tenoxicam Tenoxicam may decrease the antihypertensive activities of Acebutolol. Approved Tepoxalin Tepoxalin may decrease the antihypertensive activities of Acebutolol. Vet Approved Terazosin Acebutolol may increase the orthostatic hypotensive activities of Terazosin. Approved Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Acebutolol. Approved Teriflunomide Teriflunomide may decrease the antihypertensive activities of Acebutolol. Approved Terlipressin Acebutolol may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Acebutolol may increase the hypotensive activities of Tetrahydropalmatine. Investigational Tetryzoline The risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline. Approved Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Acebutolol. Approved, Investigational, Withdrawn Theodrenaline Acebutolol may increase the hypotensive activities of Theodrenaline. Investigational Theophylline Acebutolol may decrease the bronchodilatory activities of Theophylline. Approved Thiamylal The serum concentration of Acebutolol can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Acebutolol. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Acebutolol. Withdrawn Thiopental The serum concentration of Acebutolol can be decreased when it is combined with Thiopental. Approved, Vet Approved Thioproperazine Thioproperazine may increase the hypotensive activities of Acebutolol. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Acebutolol. Approved, Withdrawn Tiaprofenic acid Tiaprofenic acid may decrease the antihypertensive activities of Acebutolol. Approved Tibolone Acebutolol may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Acebutolol may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Timolol may increase the hypotensive activities of Acebutolol. Approved Tinoridine Tinoridine may decrease the antihypertensive activities of Acebutolol. Investigational Tizanidine Tizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Tofacitinib Tofacitinib may increase the bradycardic activities of Acebutolol. Approved, Investigational Tolazamide Acebutolol may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolazoline Tolazoline may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Tolbutamide Acebutolol may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Acebutolol. Approved, Withdrawn Tolfenamic Acid Tolfenamic Acid may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Tolmetin Tolmetin may decrease the antihypertensive activities of Acebutolol. Approved Tolonidine Acebutolol may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Acebutolol. Approved Torasemide Torasemide may increase the hypotensive activities of Acebutolol. Approved Tramazoline The risk or severity of adverse effects can be increased when Acebutolol is combined with Tramazoline. Investigational Trandolapril Trandolapril may increase the hypotensive activities of Acebutolol. Approved Tranilast Tranilast may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Acebutolol. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Acebutolol. Approved Treprostinil Treprostinil may increase the hypotensive activities of Acebutolol. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Acebutolol. Approved, Investigational, Nutraceutical Tretoquinol The risk or severity of adverse effects can be increased when Acebutolol is combined with Tretoquinol. Experimental Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol. Approved Tribenoside Tribenoside may decrease the antihypertensive activities of Acebutolol. Experimental Trichlorfon Trichlorfon may increase the bradycardic activities of Acebutolol. Vet Approved Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Trifluoperazine Trifluoperazine may increase the hypotensive activities of Acebutolol. Approved, Investigational Triflupromazine Triflupromazine may increase the hypotensive activities of Acebutolol. Approved, Vet Approved Trimazosin Acebutolol may increase the orthostatic hypotensive activities of Trimazosin. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Acebutolol. Approved, Investigational Triptolide Triptolide may decrease the antihypertensive activities of Acebutolol. Investigational Tubocurarine Tubocurarine may increase the bradycardic activities of Acebutolol. Approved Tyramine The risk or severity of adverse effects can be increased when Acebutolol is combined with Tyramine. Investigational, Nutraceutical Udenafil Udenafil may increase the antihypertensive activities of Acebutolol. Approved, Investigational Unoprostone Acebutolol may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Acebutolol may increase the orthostatic hypotensive activities of Urapidil. Investigational Valdecoxib Valdecoxib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Withdrawn Valsartan Valsartan may increase the hypotensive activities of Acebutolol. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Acebutolol. Approved Varenicline The risk or severity of adverse effects can be increased when Acebutolol is combined with Varenicline. Approved, Investigational Vemurafenib The serum concentration of Acebutolol can be increased when it is combined with Vemurafenib. Approved Venlafaxine The serum concentration of Acebutolol can be increased when it is combined with Venlafaxine. Approved Verapamil Verapamil may increase the hypotensive activities of Acebutolol. Approved Vilanterol Acebutolol may decrease the bronchodilatory activities of Vilanterol. Approved Vincamine Acebutolol may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Acebutolol may increase the hypotensive activities of Vinpocetine. Investigational Xipamide Acebutolol may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Xylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Vet Approved Zaltoprofen Zaltoprofen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Zileuton Zileuton may decrease the antihypertensive activities of Acebutolol. Approved, Investigational, Withdrawn Zimelidine The serum concentration of Acebutolol can be increased when it is combined with Zimelidine. Withdrawn Zofenopril Acebutolol may increase the hypotensive activities of Zofenopril. Experimental Zomepirac Zomepirac may decrease the antihypertensive activities of Acebutolol. Withdrawn - Food Interactions
- Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.
References
- Synthesis Reference
- US3857952
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015324
- KEGG Drug
- D02338
- KEGG Compound
- C06803
- PubChem Compound
- 1978
- PubChem Substance
- 46509113
- ChemSpider
- 1901
- BindingDB
- 25755
- ChEBI
- 2379
- ChEMBL
- CHEMBL642
- Therapeutic Targets Database
- DAP000484
- PharmGKB
- PA448011
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Acebutolol
- ATC Codes
- C07AB04 — Acebutolol
- C07AB — Beta blocking agents, selective
- C07A — BETA BLOCKING AGENTS
- C07 — BETA BLOCKING AGENTS
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 24:24.00 — Beta-adrenergic Blocking Agents
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Cardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) / Vascular Diseases 1 3 Terminated Treatment Hemangiomas 1 4 Completed Treatment Healthy Volunteers 1 Not Available Completed Treatment Arrythmias / Nonvalvular Atrial Fibrillation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Alphapharm Party Ltd.
- Amneal Pharmaceuticals
- Bryant Ranch Prepack
- Caremark LLC
- Kaiser Foundation Hospital
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Patheon Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Professional Co.
- Promius Pharma
- Dosage forms
Form Route Strength Capsule Oral 200 mg/1 Capsule Oral 400 mg/1 Tablet Oral 400 mg Tablet Oral 100 mg Tablet Oral 200 mg - Prices
Unit description Cost Unit Acebutolol hcl powder 7.08USD g Sectral 400 mg capsule 4.48USD capsule Sectral 200 mg capsule 3.37USD capsule Acebutolol HCl 400 mg capsule 1.39USD capsule Acebutolol 400 mg capsule 1.34USD capsule Sectral 400 mg Tablet 1.11USD tablet Acebutolol HCl 200 mg capsule 1.05USD capsule Acebutolol 200 mg capsule 1.01USD capsule Sectral 200 mg Tablet 0.56USD tablet Acebutolol 400 mg Tablet 0.51USD tablet Apo-Acebutolol 400 mg Tablet 0.51USD tablet Mylan-Acebutolol (Type S) 400 mg Tablet 0.51USD tablet Mylan-Acebutolol 400 mg Tablet 0.51USD tablet Novo-Acebutolol 400 mg Tablet 0.51USD tablet Nu-Acebutolol 400 mg Tablet 0.51USD tablet Rhotral 400 mg Tablet 0.51USD tablet Sectral 100 mg Tablet 0.37USD tablet Acebutolol 200 mg Tablet 0.26USD tablet Apo-Acebutolol 200 mg Tablet 0.26USD tablet Mylan-Acebutolol (Type S) 200 mg Tablet 0.26USD tablet Mylan-Acebutolol 200 mg Tablet 0.26USD tablet Novo-Acebutolol 200 mg Tablet 0.26USD tablet Nu-Acebutolol 200 mg Tablet 0.26USD tablet Rhotral 200 mg Tablet 0.26USD tablet Acebutolol 100 mg Tablet 0.17USD tablet Apo-Acebutolol 100 mg Tablet 0.17USD tablet Mylan-Acebutolol (Type S) 100 mg Tablet 0.17USD tablet Mylan-Acebutolol 100 mg Tablet 0.17USD tablet Novo-Acebutolol 100 mg Tablet 0.17USD tablet Nu-Acebutolol 100 mg Tablet 0.17USD tablet Rhotral 100 mg Tablet 0.17USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 136-138 Merck Index 13 water solubility 259 mg/L Not Available logP 1.71 HANSCH,C ET AL. (1995) Caco2 permeability -5.83 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.172 mg/mL ALOGPS logP 1.43 ALOGPS logP 1.53 ChemAxon logS -3.3 ALOGPS pKa (Strongest Acidic) 13.91 ChemAxon pKa (Strongest Basic) 9.57 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 87.66 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 94.87 m3·mol-1 ChemAxon Polarizability 38.51 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9156 Blood Brain Barrier - 0.9659 Caco-2 permeable - 0.8957 P-glycoprotein substrate Substrate 0.7378 P-glycoprotein inhibitor I Non-inhibitor 0.8557 P-glycoprotein inhibitor II Non-inhibitor 0.8664 Renal organic cation transporter Non-inhibitor 0.9466 CYP450 2C9 substrate Non-substrate 0.8102 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.5752 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8721 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9639 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.849 Biodegradation Not ready biodegradable 0.8538 Rat acute toxicity 2.0487 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9821 hERG inhibition (predictor II) Non-inhibitor 0.8555
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Acetophenones / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds / Dialkylamines show 4 more
- Substituents
- Alkyl-phenylketone / Acetophenone / Benzoyl / Phenol ether / Aryl alkyl ketone / Phenoxy compound / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / 1,2-aminoalcohol show 16 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- monocarboxylic acid amide, secondary amino compound, ether, aromatic amide, ethanolamines, propanolamine (CHEBI:2379)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Partial agonist
- General Function
- Receptor signaling protein activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
- Gene Name
- ADRB1
- Uniprot ID
- P08588
- Uniprot Name
- Beta-1 adrenergic receptor
- Molecular Weight
- 51322.1 Da
References
- van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23. [PubMed:2453744]
- Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8. [PubMed:2568935]
- Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Partial agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148]
- Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
- Lima JJ: Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):357-72. [PubMed:8968966]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
- Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:04